

Publication of Kazuo Umezawa from 2000 to 2009. Articles in Japanese are removed, so there are gaps in number.

156. N. Kashihara, S. To-e, K. Nakamura, K. Umezawa, S. Yamamura and S. Nishiyama: Synthesis and biological activities of hapalosin derivatives with modification at the C12 position. *Bioorganic & Medicinal Chemistry Letters* 10: 101-103, 2000.

157. K. Umezawa, Y. Ikeda, Y. Uchihata, H. Naganawa and S. Kondo: Chloptosin, an apoptosis-inducing dimeric cyclohexapeptide produced by *Streptomyces*. *J. Org. Chem.* 65: 459-463, 2000.

158. T. Watanabe, T. Suzuki, Y. Umezawa, T. Takeuchi, M. Otsuka and K. Umezawa : Structure-activity relationship and rational design of 3,4-dephostatin derivatives as protein tyrosine phosphatase inhibitors. *Tetrahedron* 56: 741-752, 2000.

159. M. Itabashi, K. Segawa, Y. Ikeda, S. Kondo, H. Naganawa, T. Koyano and K. Umezawa : A new bioactive steroidal saponin, furcreastatin, from the plant *Furcraea foetida*. *Carbohydrate Res.* 323: 57-62, 2000.

160. C. Okudaira, Y. Ikeda, S. Kondo, S. Furuya, Y. Hirabayashi, T. Koyano, Y. Saito and K. Umezawa : Inhibition of acidic sphingomyelinase by xanthone compounds isolated from *Garcinia speciosa*. *J. Enzyme Inhibition* 15:129-138, 2000.

161. 梅澤一夫 : アポトーシスと抗癌剤。外科治療 82 (4): 497-498, 2000.

162. N. Endo, E. Tashiro, K. Umezawa, M. Kawada, Y. Uehara, Y. Doki, I. B. Weinstein and M. Imoto: Herbimycin A induces G1 arrest through accumulation of p27Kip1 in cyclin D1-overexpressing fibroblasts. *Biochem. and Biophys. Res. Commun.* 267: 54-58, 2000.

164. Y. Saito, M. Nakamura, T. Ohno, C. Chaicharoenpong, E. Ichikawa, S. Yamamura, K. Kato and K. Umezawa: Syntheses of oxanosine and carbocyclic oxanosine derivatives as anti-HIV agents. *J. Antibiot.* 53: 309-313, 2000.

165. T. Watanabe, Y. Shiraga, T. Takeuchi, M. Otsuka, and K. Umezawa: Formal total synthesis of aglaiastatin: Pd(0)-mediated construction of benzofurocyclopentane system. *Heterocycles* 53: 1051-1064, 2000.
167. N. Matsumoto, A. Ariga, S. To-e, H. Nakamura, N. Agata, S. Hirano, J. Inoue and K. Umezawa : Synthesis of NF- $\kappa$ B activation inhibitors derived from epoxyquinomicin C. *Bioorg. Med. Chem. Lett.* 10: 865-869, 2000.
168. N. Matsumoto, N. Agata, H. Kuboki, H. Inuma, T. Sawa, T. Takeuchi and K. Umezawa: Inhibition of rat embryo histidine decarboxylase by epoxyquinomicins. *J. Antibiot.* 53: 637-639, 2000.
170. M. Seki, M. Toi, K. Kobayashi, K. Shitara, K. Umezawa, B. K. Seon, M. Kan and J. Rhim: Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. *International Journal of Oncology* 17: 525-533, 2000.
171. S. Isonishi, A. Okamoto, K. Ochiai, Y. Saito and K. Umezawa: Phosphatidylinositol 4-kinase assay in ovarian carcinoma cells. in J. M. S. Bartlett ed., *Methods in Molecular Medicine*. Vol. 39, *Ovarian Cancer: Methods and Protocols*. Humana Press, pp607-610, 2000.
172. Y. Hashimoto, H. Jing, T. Niikura, Y. Ito, A. Hagiwara, K. Umezawa, Y. Abe, Y. Murayama and I. Nishimoto: Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases. *J. Neurosci.* 20: 8401-8409, 2000.
173. A. Hagiwara, Y. Hashimoto, T. Niikura, Y. Ito, K. Terashita, Y. Kita, I. Nishimoto and K. Umezawa: Neuronal cell apoptosis by a receptor-binding domain peptide of apoE4, not through low-density lipoprotein receptor-related protein. *Biochem. Biophys. Res. Commun.* 278: 633-639, 2000.
175. Y. Saito, M. Nakamura, T. Ohno, C. Chaichoenpong, E. Ichikawa, S. Yamamura, K. Kato and K. Umezawa: Synthesis of sugar-modified derivatives of the unusual nucleoside oxanosine and its carbocyclic analogs as potential inhibitors of HIV. *J. Chem. Soc., Perkin Trans. 1* 2001: 298-304, 2001.

176. K. Umezawa, A. Ariga and N. Matsumoto: Review: Naturally occurring and synthetic inhibitors of NF- $\kappa$ B functions. *Anti-Cancer Drug Design* 15: 239-244, 2000.
178. O. Ohno, Y. Shima, Y. Ikeda, S. Kondo, K. Kato, M. Toi and K. Umezawa: Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. *International Journal of Oncology* 18: 1009-1015, 2001.
179. K. Umezawa, Y. Ikeda, O. Kawase, H. Naganawa and S. Kondo: Biosynthesis of polyoxypeptin A: novel amino acid 3-hydroxy-3-methylproline derived from isoleucine. *J. Chem. Soc., Perkin Trans. 1* 2001:1550-1553, 2001.
180. T. Suzuki, A. Hiroki, T. Watanabe, T. Yamashita, I. Takei and K. Umezawa: Potentiation of insulin-related signal transduction by a novel protein-tyrosine phosphatase inhibitor, Et-3,4-dephostatin, on cultured 3T3-L1 adipocytes. *J. Biol. Chem.* 276: 27511-27518, 2001.
181. M. Shiino, Y. Watanabe and K. Umezawa: Synthesis of N-substituted N-nitrosohydroxylamines as inhibitors of mushroom tyrosinase. *Bioorg. Med. Chem.* 9: 1233-1240, 2001.
183. K. Iikubo, Y. Ishikawa, N. Ando, K. Umezawa and S. Nishiyama: The first direct synthesis of  $\alpha$ -mangostin, a potent inhibitor of the acidic sphingomyelinase. *Tetrahedron Lett.* 43: 291-293, 2002
184. Y. Uchihata, N. Ando, Y. Ikeda, S. Kondo, M. Hamada and K. Umezawa: Isolation of a novel cyclic hexadepsipeptide pipalamycin from *Streptomyces* as an apoptosis-inducing agent. *J. Antibiot.* 55:1-5, 2002
185. A. Deguchi, K. Segawa, K. Hosaka, I. B. Weinstein and K. Umezawa: Overexpression of phosphatidylinositol synthase enhances growth and G1 progression in NIH3T3 cells. *Jpn. J. Cancer Res.* 93: 157-166, 2002.
187. A. Hiroki, H. Hatakeyama, M. Kawakami, T. Watanabe, I. Takei and K. Umezawa: Antidiabetic effect of a nitrosamine-free dephostatin analogue, methoxime-3,4-dephostatin, in db/db mice. *Biomed. Pharmacother.* 56: 173-178, 2002.

188. A. Ariga, J. Namekawa, N. Matsumoto, J. Inoue and K. Umezawa: Inhibition of TNF- $\alpha$ -induced nuclear translocation and activation of NF- $\kappa$ B by dehydroxymethyl-epoxyquinomicin. *J. Biol. Chem.* 277: 27625-27630, 2002.
190. C. Chaicharoenpong and K. Umezawa: Minireview: Molecular design and biological activities of NF- $\kappa$ B inhibitors. *Mol. Cells* 14: 163-167, 2002.
191. C. Chaicharoenpong, K. Kato and K. Umezawa: Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF- $\kappa$ B functions. *Bioorg. Med. Chem.* 10: 3933-3939, 2002.
192. K. Umezawa, Y. Ikeda, H. Naganawa and S. Kondo: Biosynthesis of the lipophylic side chain in the cyclic hexadepsipeptide antibiotic IC101. *J. Nat. Prod.* 65: 1953-1955, 2002.
193. E. Kikuchi, Y. Horiguchi, J. Nakashima, K. Kuroda, M. Oya, T. Ohigashi, N. Takahashi, Y. Shima, K. Umezawa and M. Murai: Suppression of hormone-refractory prostate cancer by a novel nuclear factor  $\kappa$ B inhibitor in nude mice. *Cancer Res.* 63: 107-110, 2003.
194. T. Hirano, M. Kizaki, K. Kato, F. Abe, N. Masuda and K. Umezawa: Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid. *Leukemia Research* 26: 1097-1103, 2002.
195. K. Umezawa: Isolation of novel cyclic peptides from *Streptomyces* that induce apoptosis in apoptosis-resistant cancer cells. *Recent Res. Devel. Organic Chem.* 6: 421-429, 2002.
196. H. Takatsuna, H. Kato, J. Gohda, T. Akiyama, A. Moriya, Y. Okamoto, Y. Yamagata, M. Otsuka, K. Umezawa, K. Semba and J. Inoue: Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase 1 (IRAK-1) in IL-1 receptor signaling. *J. Biol. Chem.* 278: 12144-12150, 2003.
197. A. Miyajima, T. Kosaka, K. Seta, T. Asano, K. Umezawa and M. Hayakawa: Novel NF- $\kappa$ B activation inhibitor prevents inflammatory injury in unilateral urethral

obstruction. *J. Urol.* 169: 1559-1563, 2003.

198. A. Hamasaki, H. Naka, F. Tamanoi, K. Umezawa and M. Otsuka: A novel metal-chelating inhibitor of protein farnesyltransferase. *Bioorg. Med. Chem. Lett.* 13: 1523-1526, 2003.

200. K. Umezawa, M. Kawakami and T. Watanabe: Molecular design and biological activities of protein-tyrosine phosphatase inhibitors. *Therapeutics & Pharmacology* 99: 15-24, 2003.

201. M. Shiino, Y. Watanabe and K. Umezawa: Synthesis and tyrosinase inhibitory activity of novel N-hydroxybenzyl-N-nitrosohydroxylamines. *Bioorg. Med. Chem.* 31: 129-135, 2003.

202. C. Chaicharoenpong, K. Kato and K. Umezawa: Preparation of radioactively labeled dehydroxymethyl-epoxyquinomicin, an NF- $\kappa$ B inhibitor. *Drugs Exptl. Clin. Res.* 29: 1-3, 2003.

203. K. Toshima, T. Kimura, R. Takano, T. Ozawa, A. Ariga, Y. Shima, K. Umezawa and S. Matsumura: Molecular design, chemical synthesis and biological evaluation of quinoxaline-carbohydrate hybrids as novel and selective photo-induced DNA cleaving and cytotoxic agents. *Tetrahedron* 59: 7057-7066, 2003.

204. H. Prinz, Y. Ishii, T. Hirano, T. Stoiber, J. A. C. Gomez, P. Schmidt, H. Duesmann, A. M. Burger, J. H. M. Prehn, E. G. Guenther, E. Unger and K. Umezawa: Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents-Synthesis, antiproliferative activity and inhibition of tubulin polymerization. *J. Med. Chem.* 46: 3382-3394, 2003.

205. M. Hamada, K. Iikubo, Y. Ishikawa, A. Ikeda, K. Umezawa and S. Nishiyama: Biological activities of  $\alpha$ -mangostin derivatives against acidic sphingomyelinase. *Bioorg. Med. Chem. Lett.* 13: 3151-3153, 2003.

206. J. Gohda, J. Inoue and K. Umezawa: Down-regulation of TNF receptors by conophylline in human T-cell leukemia cells. *Int. J. Oncol.* 23: 1373-1379, 2003.

207. K. Umezawa, A. Hiroki, M. Kawakami, H. Naka, I. Takei, T. Ogata, I. Kojima, T. Koyano, T. Kowithayakorn, H. S. Pang and T. S. Kam: Induction of insulin production in rat pancreatic acinar carcinoma cells by conophylline. *Biomed. Pharmacother.* 57: 341-350, 2003.
209. Y. Horiguchi, K. Kuroda, J. Nakashima, M. Murai and K. Umezawa: Antitumor effect of a novel nuclear factor- $\kappa$ B activation inhibitor in bladder cancer cells. *Expert Rev. Anticancer Ther.* 3: 793-798, 2003.
210. S. Atsumi, A. Nagasawa, T. Koyano, T. Kowithayakorn and K. Umezawa: Suppression of TGF- $\beta$  signaling by conophylline via upregulation of c-Jun expression. *Cell. Mol. Life Sci.* 60: 2516-2525, 2003.
211. M. Murata, K. Midorikawa, M. Koh, K. Umezawa and S. Kawanishi: Genistein and daizein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. *Biochemistry* 43: 2569-2577, 2004.
212. Y. Suzuki, C. Sugiyama, O. Ohno and K. Umezawa: Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF- $\kappa$ B inhibitor. *Tetrahedron* 60: 7061-7066, 2004.
213. O. Ohno, Y. Ikeda, R. Sawa, M. Igarashi, N. Kinoshita, Y. Suzuki, K. Miyake, and K. Umezawa: Isolation of heptadepsin, a novel bacterial cyclic depsipeptide that inhibits lipopolysaccharide activity. *Chemistry & Biology* 11: 1059-1070, 2004.
214. T. Ogata, L. Li, S. Yamada, Y. Yamamoto, Y. Tanaka, I. Takei, K. Umezawa and I. Kojima: Promotion of b cell differentiation by conophylline in fetal and neonatal rat pancreas. *Diabetes* 53: 2596-2602, 2004.
216. H. Takatsuna and K. Umezawa: Screening of bioactive metabolites for pancreatic regeneration chemotherapy. *Biomed. Pharmacother.* 58:610-613, 2004.
217. H. Ohgawara, K. Edamura, M. Kawakami and K. Umezawa: Diabetes mellitus: rational basis, clinical approach and future therapy. *Biomed. Pharmacother.* 58: 605-609, 2004.

218. D. V. Starenki, H. Namba, V. A. Saenko, A. Ohtsuru, S. Maeda, K. Umezawa and S. Yamashita: Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, DHMEQ. Clin. Cancer Res. 10: 6821-6829, 2004.
219. M. Fujii, K. Umezawa and A. Arata: Dopaminergic effects on respiratory rhythm generation in rat brainstem-spinal cord preparation. Neuroscience Res. 50:355-359, 2004.
220. G. Matsumoto, J. Namekawa, M. Muta, T. Nakamura, H. Bando, K. Tohyama, M. Toi and K. Umezawa: Targeting of NF- $\kappa$ B pathways by DHMEQ, a novel inhibitor of breast carcinomas: Anti-tumor and anti-angiogenic activity *in vivo*. Clin. Cancer Res. 11: 1287-1293, 2005.
221. M. Nakamura, T. Ogawa, A. Yokono, S. Nakamori, T. Ohno and K. Umezawa: Synergistic antiviral effect of oxanosine and ddI against human immunodeficiency virus. Biomed. Pharmacother. 59: 47-50, 2005.
222. M. Watanabe, M. Z. Dewan, T. Okamura, M. Sasaki, K. Itoh, M. Higashihara, H. Mizoguchi, M. Honda, T. Sata, T. Watanabe, N. Yamamoto, K. Umezawa and R. Horie: A novel NF- $\kappa$ B inhibitor DHMEQ selectively targets constitutive NF- $\kappa$ B activity and induces apoptosis of multiple myeloma cells *in vitro* and *in vivo*. Int. J. Cancer 114: 32-38, 2005.
223. D. Kamiya, Y. Uchihata, E. Ichikawa, K. Kato and K. Umezawa: Reversal of drug resistance by COTC based on intracellular glutathione and glyoxalase I. Biorg. Med. Chem. Lett. 15:1111-1114, 2005.
224. H. Takatsuna, M. Asagiri, T. Kubota, K. Oka, T. Osada, C. Sugiyama, H. Saito, K. Aoki, K. Ohya, H. Takayanagi and K. Umezawa: Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF- $\kappa$ B inhibitor, through downregulation of NFATc1. J. Bone Mineral Res. 20: 653-661, 2005.
225. H. Takatsuna, S. Morita, T. Nagatsu, M. Sawada and K. Umezawa: Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF- $\kappa$ B inhibitor. Biomed. Pharmacother. 59: 318-322, 2005.

226. O. Ohno, Y. Shima, Y. Ikeda, Y. Kawai, K. Sakurai, K. Watanabe, and K. Umezawa: Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF- $\kappa$ B inhibitor DHMEQ under flow. *Oncology Res.* 15: 189-198, 2005.
227. H. Tatetsu, Y. Okuno, M. Nakamura, F. Matsuno, T. Sonoki, I. Taniguchi, S. Umeda, K. Umezawa, H. Mitsuya and H. Hata: A novel nuclear factor kappa B inhibitor induced apoptosis of multiple myeloma cells. *Mol. Cancer Ther.* 4: 1114-1120, 2005.
228. K. Wakamatsu, T. Nanki, N. Miyasaka, K. Umezawa and T. Kubota: Effect of a small molecule inhibitor of nuclear factor- $\kappa$ B nuclear translocation in a murine model of arthritis and cultured human synovial cells. *Arthritis Research & Therapy* 7: 1348-1359, 2005.
229. G. Matsumoto, M. Muta, K. Umezawa, T. Suzuki, K. Mitsumi, K. Tsuruta, A. Okamoto and M. Toi: Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF- $\kappa$ B inhibitor. *Int. J. Oncology* 27: 1247-1255, 2005.
230. M. Watanabe, T. Ohsugi, M. Shoda, T. Ishida, S. Aizawa, M. Maruyama-Nagai, A. Utsunomiya, S. Koga, Y. Yamada, S. Kamihira, A. Okayama, H. Kikuchi, K. Uozumi, K. Yamaguchi, M. Higashihara, K. Umezawa, T. Watanabe and R. Horie.: Dual targeting of transformed and untransformed HTLV-1-infected T-cells by DHMEQ, a potent and selective inhibitor of NF- $\kappa$ B, as a strategy for chemoprevention and therapy of adult T cell leukemia. *Blood* 106: 2462-2471, 2005.
231. M. Watanabe, M. Sasaki, K. Itoh, M. Higashihara, K. Umezawa, M. E. Kadin, L. J. Abraham, T. Watanabe and R. Horie: JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma. *Cancer Res.* 65: 7628-7634, 2005.
232. K. Kuroda, Y. Horiguchi, J. Nakashima, E. Kikuchi, K. Kanao, A. Miyajima, T. Ohigashi, K. Umezawa and M. Murai: Prevention of cancer cachexia by a novel nuclear factor  $\kappa$ B inhibitor in prostate cancer. *Clin. Cancer Res.* 11: 5590-5594, 2005.



233. T. Ohsugi, R. Horie, T. Kumasaka, A. Ishida, T. Ishida, K. Yamaguchi, T. Watanabe, K. Umezawa and T. Urano: In vivo antitumor activity of the NF- $\kappa$ B inhibitor dehydroxymethyl-epoxyquinomicin in a mouse model of adult T-cell leukemia. *Carcinogenesis* 26: 1382-1388, 2005.
234. T. Ohsugi, T. Kumasaka, A. Ishida, T. Ishida, R. Horie, T. Watanabe, K. Umezawa and K. Yamaguchi: In vitro and in vivo antitumor activity of the NF-kappa B inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. *Leuk. Res.* 30:90-97, 2006.
235. T. Takahashi, O. Ohno, Y. Ikeda, R. Sawa, Y. Homma, M. Igarashi, K. Umezawa: Inhibition of lipopolysaccharide activity by a bacterial cyclic lipopeptide surfactin. *J. Antibiot.* 59: 35-43, 2006.
236. C. Culmsee, N. Gerling, S. Landshamer, B. Rickerts, H.-J. Duchstein, K. Umezawa, S. Klumpp and J. Krieglstein: Nitric oxide donors induce neurotrophin-like survival signaling and protect neurons against apoptosis. *Molecular Pharmacology* 68:1006-1017, 2005.
237. M. Fujii, K. Umezawa and A. Arata: Dopamine desynchronizes the pace-making neuronal activity of rat respiratory rhythm generation. *Eur. J. Neurosci.* 23: 1015-1027, 2006.
238. I. Kojima and K. Umezawa: Conophylline: A novel differentiation inducer for pancreatic  $\beta$  cells. *International Journal of Biochemistry & Cell Biology* 38: 923-930, 2006.
239. A. Sato, M. Oya, K. Ito, R. Mizuno, Y. Horiguchi, K. Umezawa, M. Hayakawa and M. Murai: Survivin associates with cell proliferation in renal cancer cells: Regulation of surviving expression by insulin-like growth factor-1, interferon- $\gamma$  and a novel NF- $\kappa$ B inhibitor. *Int. J. Oncology* 28: 841-846, 2006.
241. R. Horie, M. Watanabe, T. Okamura, M. Taira, M. Shoda, T. Motoji, A. Utsunomiya, T. Watanabe, M. Higashihara and K. Umezawa: DHMEQ, a new NF- $\kappa$ B inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. *Leukemia* 20: 800-806, 2006.

242. R. Horie, T Watanabe and K. Umezawa: Blocking NF- $\kappa$ B as a potential strategy to treat adult T-cell leukemia/lymphoma. *Drug News Perspect.* 19: 201-209, 2006.
244. M. Fujii, K. Umezawa and A. Arata: Adrenaline contributes to prenatal respiratory maturation in rat medulla-spinal cord preparation. *Brain Res.* 1090: 45-50, 2006.
246. K. Umezawa: Inhibition of tumor growth by NF- $\kappa$ B inhibitors. *Cancer Science* 97: 990-995, 2006.
247. E. Suzuki and K. Umezawa: Inhibition of macrophage activation and phagocytosis by a novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin. *Biomed. Pharmacother.* 60: 578-586, 2006.
248. Z. Wang, M. Igarashi, Y. Ikeda, R. Horie and K. Umezawa: Inhibition of NFkappa B activation by 9-methylstreptimidone isolated from *Streptomyces*. *Heterocycles* 69: 377-383, 2006.
249. H. Ruan, M. Masuda, A. Ito, K. Umezawa, T. Nakashima, R. Yasumatsu, Y. Kuratomi, T. Yamamoto, I. B. Weinstein and S. Komune: Effects of a novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. *Head & Neck* 2006:158-164.
250. N. Komura, Y. Ikeda, N. Masuda, Y. Umezawa, K. Ito, M. Kizaki and K. Umezawa: Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. *Leuk. Res.* 31: 301-313, 2007.
251. R. Kitamura, T. Ogata, Y. Tanaka, K. Motoyoshi, M. Seno, I. Takei, K. Umezawa and I. Kojima: Conophylline and betacellulin- $\delta$ 4: an effective combination of differentiation factors for pancreatic  $\beta$  cells. *Endocrine J.* 54: 255-264, 2007.
252. M. Watanabe, M. Z. Dewan, M. Taira, M. Shoda, M. Honda, T. Sata, M. Higashihara, M. E. Kadin, T. Watanabe, N. Yamamoto, K. Umezawa and R. Horie: I $\kappa$ B $\alpha$  independent induction of NF- $\kappa$ B and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. *Laboratory Investigation* 87: 372-382, 2007.

253. A. Katsman, K. Umezawa and B. Bonavida: Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. *Drug Resistance Updates* 10: 1-12, 2007.
254. I. Palona, H. Namba, N. Mitsutake, D. Starenki, A. Podtcheko, I. Sedliarou, A. Ohtsuru, V. Saenko, Y. Nagayama, K. Umezawa and S. Yamashita: BRAFV600E promotes invasiveness of thyroid cancer cells through NF- $\kappa$ B activation. *Endocrinology* 147:5699-5707, 2006.
255. S. Ueki, K. Yamashita, T. Aoyagi, S. Haga, T. Suzuki, T. Itoh, M. Taniguchi, T. Shimamura, H. Furukawa, M. Ozaki, K. Umezawa and S. Todo: Control of allograft rejection by applying a novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin. *Transplantation*, 82: 1720-1727, 2006.
256. N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, Y. Ozawa, K. Yamashiro, M. Inoue, K. Tsubota, K. Umezawa and S. Ishida: Suppression of diabetes-induced retinal inflammation by blocking angiotensin II type 1 receptor or its downstream NF- $\kappa$ B pathway. *Investigative Ophthalmology and Visual Science* 48: 4342-4350, 2007.
257. N. Kimura, Y. Miyakawa, K. Kohmura, K. Umezawa, Y. Ikeda and M. Kizaki: Targeting NF- $\kappa$ B and induction of apoptosis by novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. *Leukemia Research*, 31: 1529-1535, 2007.
259. E. Suzuki, K. Umezawa and B. Bonavida: Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: Involvement in chemosensitization to drug-induced apoptosis. *Oncogene* 26: 6184-6189, 2007.
260. N. Komura, M. Asakawa, K. Umezawa and K. Segawa: Tyrosine kinase inhibitor methyl-2,5-dihydroxycinnamate induces PML nuclear body formation and apoptosis in tumor cells. *Exp. Cell Res.* 313: 2753-2765, 2007.
261. T. Ohsugi, T. Kumasaka, S. Okada, T. Ishida, K. Yamaguchi, R. Horie, T. Watanabe, and K. Umezawa: Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with Tax-deficient adult T-cell leukemia-derived cell lines. *Cancer Letters* 257: 206-215, 2007.

262. Y. N. Kimura, K. Watari, A. Fotovati, F. Hosoi, K. Yasumoto, H. Izumi, K. Kohno, K. Umezawa, H. Iguchi, K. Shirouzu, S. Takamori, M. Kuwano and M. Ono: Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. *Cancer Science* 98: 2009-2018, 2007.
263. Y. Komi, O. Ohno, Y. Suzuki, M. Shimamura, K. Shimokado, K. Umezawa and S. Kojima: Inhibition of tumor angiogenesis by targeting endothelial ATP synthase with sangivamycin. *Japan Journal of Clinical Oncology*, 37:867-873, 2007.
265. T. Kubota, M. Hoshino, K. Aoki, K. Ohya, Y. Komano, T. Nanki, N. Miyasaka and K. Umezawa: NF- $\kappa$ B inhibitor DHMEQ suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANCL, OPG or M-CSF. *Arthritis Research & Therapy* <http://arthritis-research.com/content/9/5/R97>, 2007.
266. S. Baritaki, E. Suzuki, K. Umezawa, D. A. Spandidos, J. Berenson, T. R. Daniels, M. L. Penichet, A. R. Jazirehi, M. Palladino and B. Bonavida: Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. *J. Immunol.* 180: 6199-6210, 2008.
267. Y. Saisho, H. Hirose, C. Horimai, K. Miyashita, I. Takei, K. Umezawa and H. Itoh: Effects of DHMEQ, a novel nuclear factor- $\kappa$ B inhibitor on beta cell dysfunction in INS cells. *Endocrine J.* 55: 433-438, 2008.
268. E. Hisanaga, K.-Y. Park, S. Yamada, H. Hashimoto, T. Takeuchi, M. Mori, M. Seno, K. Umezawa, I. Takei and I. Kojima: A simple method to induce differentiation of murine bone marrow mesenchymal cells to insulin-producing cells using conophylline and betacellulin-delta4. *Endocrine J.* 55: 535-543, 2008.
269. A. Miyake, Z. Dewan, T. Ishida, M. Watanabe, M. Honda, T. Sata, N. Yamamoto, K. Umezawa, T. Watanabe and R. Horie: Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF- $\kappa$ B inhibitor DHMEQ. *Microbes and Infection* 10: 748-756, 2008.
270. K. Izumi-Nagai, N. Nagai, K. Ohgami, S. Satofuka, Y. Ozawa, K. Tsubota, K. Umezawa, S. Ohno, Y. Oike and S. Ishida: Macular pigment lutein is anti-inflammatory

in preventing choroidal neovascularization. *Arterioscler. Thromb. Vasc. Biol.*, *Arterioscler Thromb Vasc Biol.* 2007 Dec (12): 2555-2562, 2007.

271. T. Kosaka, A. Miyajima, E. Kikuchi, Y. Horiguchi, K. Umezawa, T. Ohigashi, J. Nakashima, T. Asano and M. Oya: The novel NF- $\kappa$ B activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats. *Nephron Exp. Nephrol.* 110: e17–e24, 2008.

272. T. Suzuki, K. Yamashita, W. Jomen, S. Ueki, T. Aoyagi, M. Fukai, H. Furukawa, K. Umezawa, M. Ozaki and S. Todo: The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. *J. Surg. Res.* 149: 69-75, 2008.

274. M. Watanabe, M. Nakashima, T. Togano, M. Higashihara, T. Watanabe, K. Umezawa and R. Horie: Identification of the RelA domain responsible for action of a new NF- $\kappa$ B inhibitor DHMEQ. *Biochem. Biophys. Res. Commun.* 376: 310-314, 2008.

275. C. Nishioka, T. Ikezoe, Y. Jing, K. Umezawa and A. Yokoyama: DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells. *Immunology* 124: 198-205, 2008.

276. E. Suzuki, C. Sugiyama and K. Umezawa: Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages. *Biomed. Pharmacother.* 63: 351-358, 2009.

277. K. Horiuchi, H. Morioka, K. Nishimoto, M. Susa, R. Nakayama, A. Kawai, H. Sonobe, H. Takaishi, T. Ozaki, H. Yabe, K. Umezawa, Y. Toyama: Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF- $\kappa$ B inhibitor, Dehydroxymethylepoxyquinomicin (DHMEQ). *Cancer Letters* 272: 336-344, 2008.

278. M. I. Vega, M. Martinez-Paniagua, A. R. Jazirehi, S. Huerta-Yepez, K. Umezawa, O. Martinez-Maza and B. Bonavida: The NF- $\kappa$ B inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. *Leukemia and Lymphoma* 49:1982-1994, 2008.

281. M. Tachibana, C. Matsui, Y. Takeuchi, E. Suzuki and K. Umezawa: Inhibition of NF-kappa B activation by penicillic acid and dihydropenicillic acid isolated from fungi. *Heterocycles* 76: 1561-1569, 2008.
282. M. Yamamoto, R. Horie, M. Takeiri, I. Kozawa and K. Umezawa: Inactivation of nuclear factor kappa B components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. *J. Med. Chem.*, 51: 5780-5788, 2008.
283. E. Watanabe, N. Mochizuki, H. Ajima, K. Ohno, M. Shiino, K. Umezawa, M. Fukai, M. Ozaki, H. Furukawa, S. Todo, S. Kishino: A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. *J. Chromatography B* 871: 32-36, 2008.
284. B. Bonavida, A. R. Jazirehi, M. I. Vega, S. Huerta-Yepez,, K. Umezawa and E. Suzuki: Chemo-immunosensitization of resistant B-NHL as a result of rituximab (anti-CD20 mAb)-mediated inhibition of cell survival signaling pathways. in B. Bonavida (editor) *Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy*, pp29-40, Springer, 2008.
285. S. Makino, N. Mitsutake, M. Nakashima, V. A. Saenko, A. Ohtsuru, K. Umezawa, K. Tanaka, A. Hirano, S. Yamashita: DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. *J. Dermatol. Sci.* 51: 171-180, 2008.
286. Z. Meng, N. Mitsutake, M. Nakashima, D. Starenki, M. Matsuse, S. Takakura, H. Namba, V. Saenko, K. Umezawa, A. Ohtsuru, S. Yamashita: Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. *Endocrinology* 149: 5357-5365, 2008.
287. Y. Ishikawa, M. Tachibana, C. Matsui, R. Obata, K. Umezawa and S. Nishiyama: Synthesis and biological evaluation on novel analogs of 9-methyl-streptimidone, an inhibitor of NF- $\kappa$ B. *Bioorg. Med. Chem. Lett.* 19: 1726-1728, 2009.

289. E. Suzuki, Y. Ninomiya and K. Umezawa: Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappa B inhibitor (-)-DHMEQ. *Biochem. Biophys. Res. Commun.* 379: 379-383, 2009.
290. E. Suzuki, H. Ogura, K. Kato, I. Takei, Y. Kabe, Hiroshi Handa and K. Umezawa: Preparation of conophylline affinity nanobeads and identification of a target protein. *Bioorg. Med. Chem.* 17: 6185-6195, 2009.
291. J. Inumaru, O. Nagano, E. Takahashi, T. Ishimoto, S. Nakamura, Y. Suzuki, S. Niwa, K. Umezawa, H. Tanihara and H. Saya: Molecular mechanisms regulating dissociation of cell-cell junction of epithelial cells by oxidative stress. *Genes Cells* 14: 706-716, 2009.
292. N. Dabaghmanesh, A. Matsubara, A. Miyake, K. Nakano, T. Ishida, H. Katano, R. Horie, K. Umezawa and T. Watanabe: Transient inhibition of NF- $\kappa$ B by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. *Cancer Science* 100: 737-746, 2009.
293. I. Kozawa, K. Kato, T. Teruya, K. Suenaga and K. Umezawa: Unusual intramolecular N>O acyl group migration occurring during conjugation of (-)-DHMEQ with cysteine. *Bioorg. Med. Chem. Lett.* 19: 5380-5382, 2009.
294. T. Saitoh, E. Suzuki, A. Takasugi, R. Obata, Y. Ishikawa, K. Umezawa and S. Nishiyama: Efficient synthesis of ( $\pm$ )-parasitenone, a novel inhibitor of NF- $\kappa$ B. *Bioorg. Med. Chem. Lett.* 19: 5383-5386, 2009.
295. K. Toshima, S. Tanimoto, K. Tsumura, K. Umezawa and D. Takahashi: Target-selective degradation of cancer-related proteins by novel photosensitizers for molecular-targeted photodynamic therapy. (Review article) *Cancer Science* 100: 1581-1584, 2009.
296. T. Kubota, Y. Fukuya, R. Hashimoto, T. Kanda, H. Suzuki, Y. Okamura, T. Nanki, N. Miyasaka and K. Umezawa: Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome: an attractive target for the NF- $\kappa$ B-specific inhibitor DHMEQ. *Ann. N. Y. Acad. Sci.* 1173: 137-145, 2009.

297. N. Tsukamoto, S. Okada, Y. Onami, Y. Sasaki, K. Umezawa and Y. Kawakami: Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. *Clin. Cancer Res.* 15: 5733-5743, 2009.
300. M. Hamada, Y. Inami, Y. Nagai, T. Higashi, M. Shoji, S. Ogawa, K. Umezawa, T. Sugai: Enzyme-catalyzed resolution of 3,8-dioxatricyclo[3.2.1.0<sup>2,4</sup>]octane-6-carboxylic esters and the application to the synthesis of 3-epishikimic acid. *Tetrahedron: Asymmetry* 20: 2105-2111, 2009.
301. T. Togano, M. Sasaki, M. Watanabe, M. Nakashima, T. Tsuruo, K. Umezawa, M. Higashihara, T. Watanabe and R. Horie: Induction of oncogene addiction shift to NF- $\kappa$ B by camptothecin in solid tumor cells. *Biochem. Biophys. Res. Commun.* 390: 60-64, 2009.
302. M. Fujii, I. Takei and K. Umezawa: Antidiabetic effect of plant extract containing conophylline by oral administration in streptozotocin-treated and Goto-Kakizaki rats. *Biomedicine & Pharmacotherapy* 63: 710-716, 2009.
303. T. Chiba, Y. Kondo, S. Shinozaki, E. Kaneko, A. Ishigami, N. Maruyama, K. Umezawa and K. Shimokado: A selective NF- $\kappa$ B inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. *J. Atherosclerosis Thrombosis* 13: 308-313, 2009.
304. N. Lampiasi, A. Azzolina, N. D'Alessandro, K. Umezawa, J. A. McCubrey, G. Montalto and M. Cervello: Antitumor effects of DHMEQ, a novel NF- $\kappa$ B inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. *Molecular Pharmacology* 76:290-300, 2009.